Live: Will Webull Crush Q2 Earnings Tonight After Rising 7.5% Today?

Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

736 Articles

Chris Lange | May 25, 2016 at 8:20 AM EDT

Short Sellers Grow More Selective on Major Biotechs

The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in…

Paul Ausick | May 19, 2016 at 4:04 PM EDT

The 52-Week Low Club for Thursday

May 19, 2016: Here are four stocks trading with heavy volume among 81 equities making new 52-week lows in Thursday’s…

Chris Lange | May 11, 2016 at 8:15 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these…

Chris Lange | May 3, 2016 at 1:35 PM EDT

Can Gilead Shares Still Really Rise to $150?

Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have…

Chris Lange | May 1, 2016 at 10:50 AM EDT

Analysts Make Major Changes to Top Biotech Ratings

With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls…

Jon C. Ogg | Apr 29, 2016 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital…

Chris Lange | Apr 28, 2016 at 4:52 PM EDT

Gilead Results Trip Over Both the Top and Bottom Lines

Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in…

Chris Lange | Apr 27, 2016 at 8:10 AM EDT

Short Sellers Run for Cover From Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest decreased across the board…

Sam Stebbins | Apr 26, 2016 at 6:57 AM EDT

The World’s 15 Top Selling Drugs

Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also…

Lee Jackson | Apr 13, 2016 at 9:50 AM EDT

UBS Makes Major Changes to Equity Focus List for Q2

In a recent report, UBS made some significant changes to its Equity Focus list. The analysts look to go a…

Chris Lange | Apr 12, 2016 at 9:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Apr 6, 2016 at 10:05 AM EDT

5 Biotechs With the Most Upside This Earnings Cycle

Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help…

Chris Lange | Mar 23, 2016 at 9:05 AM EDT

How Ionis Pharma Beat a Biotech Giant

Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.

Jon C. Ogg | Mar 16, 2016 at 11:20 AM EDT

Why One Analyst Sees Gilead Worth 66% More

Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on…

Chris Lange | Mar 10, 2016 at 8:05 AM EST

Short Sellers Back Off of Major Biotechs

The February 29 short interest data have been compared with the previous report, and short interest decreased across the board…

1 … 26 27 28 29 30 … 50

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Grow More Selective on Major Biotechs

The 52-Week Low Club for Thursday

Short Sellers Run for Cover From Major Biotechs

Can Gilead Shares Still Really Rise to $150?

Analysts Make Major Changes to Top Biotech Ratings

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

Gilead Results Trip Over Both the Top and Bottom Lines

Short Sellers Run for Cover From Major Biotechs

The World’s 15 Top Selling Drugs

UBS Makes Major Changes to Equity Focus List for Q2

Short Sellers Run for Cover From Major Biotechs

5 Biotechs With the Most Upside This Earnings Cycle

How Ionis Pharma Beat a Biotech Giant

Why One Analyst Sees Gilead Worth 66% More

Short Sellers Back Off of Major Biotechs

Live: Will Webull Crush Q2 Earnings Tonight After Rising 7.5% Today?

Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection

Which Big Bank Stock Has Dominated in 2026: Bank of America, Wells Fargo, or Bank of New York Mellon Corp.?

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

At 88, He Still Climbs Ladders at His Shoe Store. His Age Ended the Earnings Test, but Not the Social Security Tax.

Housing Starts Plunge 10% as Mortgage Rates Climb to 6.75%, Builders Brace for Demand Collapse

Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection

Which Big Bank Stock Has Dominated in 2026: Bank of America, Wells Fargo, or Bank of New York Mellon Corp.?

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Grow More Selective on Major Biotechs

The 52-Week Low Club for Thursday

Short Sellers Run for Cover From Major Biotechs

Can Gilead Shares Still Really Rise to $150?

Analysts Make Major Changes to Top Biotech Ratings

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

Gilead Results Trip Over Both the Top and Bottom Lines

Short Sellers Run for Cover From Major Biotechs

The World’s 15 Top Selling Drugs

UBS Makes Major Changes to Equity Focus List for Q2

Short Sellers Run for Cover From Major Biotechs

5 Biotechs With the Most Upside This Earnings Cycle

How Ionis Pharma Beat a Biotech Giant

Why One Analyst Sees Gilead Worth 66% More

Short Sellers Back Off of Major Biotechs

Live: Will Webull Crush Q2 Earnings Tonight After Rising 7.5% Today?

Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection

Which Big Bank Stock Has Dominated in 2026: Bank of America, Wells Fargo, or Bank of New York Mellon Corp.?

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

Featured Reads

At 88, He Still Climbs Ladders at His Shoe Store. His Age Ended the Earnings Test, but Not the Social Security Tax.

Housing Starts Plunge 10% as Mortgage Rates Climb to 6.75%, Builders Brace for Demand Collapse